Inactive Instrument

Highlights Pandion Therapeutics, Inc.

Equities

PAND

US6983401067

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Merck : Completes Pandion Therapeutics Acquisition	01/04/21	MT
Merck Sharp & Dohme Corp. completed the acquisition of Pandion Therapeutics, Inc..	31/03/21	CI
Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody	16/03/21	CI
Pandion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	12/03/21	CI
Pandion Therapeutics : Shares More Than Double Premarket on Takeover by Merck	25/02/21	DJ
Pandion Therapeutics : Merck to buy drug developer Pandion Therapeutics for $1.85 billion	25/02/21	RE
Merck : to Acquire Pandion Therapeutics for $1.85 Billion in All-Cash Deal	25/02/21	MT
Merck : to Buy Pandion Therapeutics for $1.85 Billion	25/02/21	DJ
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Pandion Therapeutics, Inc. for $1.7 billion.	24/02/21	CI
Pandion Therapeutics : Drug Delays Hyperglycemia in Preclinical Trial on Mice; Stock Climbs	22/02/21	MT
Pandion Therapeutics, Inc. Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease	22/02/21	CI
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells	04/01/21	CI
FairJourney Biologics and IONTAS Enter Antibody Discovery Agreement with Pandion Therapeutics Using Novel Discovery Platforms	23/11/20	CI
Pandion Therapeutics : Earnings Flash (PAND) PANDION THERAPEUTICS Posts Q3 Revenue $2.6M	16/11/20	MT
Pandion Therapeutics, Inc. Reports Unaudited Condensed Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2020	16/11/20	CI
Pandion Therapeutics, Inc. Announces Presentation of Preclinical Data Highlighting the Potential of its Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at the Federation of Clinical Immunology Societies 2020 Virtual Annual Meeting	28/10/20	CI
Pandion Therapeutics, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2020	31/08/20	CI
Pandion Therapeutics, Inc. has completed an IPO in the amount of $135 million.	17/07/20	CI
Pandion Therapeutics Announces Pricing of Initial Public Offering	17/07/20	GL
Pandion Therapeutics, Inc. has filed an IPO in the amount of $75 million.	26/06/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pandion Therapeutics, Inc.

Equities

PAND

US6983401067

Highlights

Filters